# Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

> **NCT06320405** · PHASE1,PHASE2 · RECRUITING · sponsor: **OHSU Knight Cancer Institute** · enrollment: 38 (estimated)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm
- Recurrent Malignant Solid Neoplasm
- Refractory Malignant Solid Neoplasm

## Interventions

- **BIOLOGICAL:** Axatilimab
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Paclitaxel
- **PROCEDURE:** Positron Emission Tomography
- **BIOLOGICAL:** Retifanlimab

## Key facts

- **NCT ID:** NCT06320405
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-21
- **Primary completion:** 2027-04-01
- **Final completion:** 2029-04-01
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2025-12-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06320405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06320405, "Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06320405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*